IP Library Granted Patent US 12,251,391
Granted Patent B2
US 12,251,391 · App. 17/291,481 · Granted Mar 18, 2025

Methods of supporting gastrointestinal homeostasis

Inventors: Britta Blokker (Saint-Louis, FR); Stephane Duval (Carspach, FR); John Michael Geremia (Watertown, MA); Estefania Perez Calvo (Rosenau, FR); Nathalie Richard (Mulhouse, FR); Jerome Schmeisser (Mulhouse, FR); Nicole Seifert (Rheinfelden, CH); Viviane Verlhac (Dietwiller, FR)
Assignee: DSM IP ASSETS B.V.
A61K31/702A23K20/163A23K50/30A23K50/75A61K9/0053A61P1/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,251,391
App. No.
17/291,481
Granted
Mar 18, 2025
Kind
B2
Abstract

The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to prevent or treat dysfunctions in a gastrointestinal barrier. The present disclosure further relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to prevent or treat infections.

Claims (13)

1. A method of treating a gastrointestinal barrier dysfunction or decreasing the permeability of a gastrointestinal barrier, in an animal in need thereof, the method comprising: administering a nutritional composition that comprises a base nutritional composition and a synthetic oligosaccharide preparation to said animal, the synthetic oligosaccharide preparation comprising at least n fractions of oligosaccharides each having a distinct degree of polymerization selected from 1 to n (DP1 to DPn fractions), wherein n is an integer greater than 3; and wherein each of a DP1 and DP2 fraction independently comprises from about 0.5% to about 15% of anhydro-subunit containing oligosaccharides by relative abundance as determined by mass spectrometry, wherein said anhydro-subunit containing oligosaccharides are selected from the group consisting of anhydro-glucose, anhydro-galactose, anhydro-mannose and anhydro-fructose, to thereby treat said gastrointestinal barrier dysfunction or decrease the permeability of said gastrointestinal barrier.

2. The method of claim 1 , wherein permeability of a gastrointestinal barrier of said animal is decreased relative to permeability of said gastrointestinal barrier of said animal prior to said administering said synthetic oligosaccharide preparation.

3. The method of claim 2 , wherein said decrease is at least about a 0.5%, 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, or 30% decrease relative to said permeability of said gastrointestinal barrier of said animal prior to said administering said synthetic oligosaccharide preparation.

4. The method of claim 3 , wherein said permeability of said gastrointestinal barrier is determined from a blood, fecal, or urine sample from said animal.

5. The method of claim 4 , wherein said permeability is measured by determining a level of at least one microbial species in said blood, fecal, or urine sample.

6. The method of claim 4 , wherein said decrease permeability of said gastrointestinal barrier is mediated indirectly by said synthetic oligosaccharide preparation.

7. The method of claim 1 , wherein at least one symptom associated with said gastrointestinal barrier dysfunction is ameliorated.

8. The method of claim 1 , wherein said gastrointestinal barrier dysfunction is associated with or caused by an infection.

9. A method of treating an infection in an animal in need thereof, the method comprising: administering a nutritional composition comprising a base nutritional composition and a synthetic oligosaccharide preparation to said animal, the synthetic oligosaccharide preparation comprising at least n fractions of oligosaccharides each having a distinct degree of polymerization selected from 1 to n (DP1 to DPn fractions), wherein n is an integer greater than 3; and wherein each of a DP1 and DP2 fraction independently comprises from about 0.5% to about 15% of anhydro-subunit containing oligosaccharides by relative abundance as determined by mass spectrometry, wherein said anhydro-subunit containing oligosaccharides are selected from the group consisting of anhydro-glucose, anhydro-galactose, anhydro-mannose and anhydro-fructose, to thereby treat said infection.

10. The method of claim 9 , wherein a level of at least one immune cell in a sample from said animal is increased relative to a level of said at least one immune cell in a sample from said animal prior to administration of said nutritional composition that comprises said synthetic oligosaccharide preparation.

11. The method of claim 10 , wherein said increase is at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% increased relative to said level of said at least one immune cell prior to administration of said nutritional composition comprising said synthetic oligosaccharide preparation.

12. The method of claim 11 , wherein a level of at least one pro-inflammatory cytokine in a sample from said animal is increased relative to a level of said at least one pro-inflammatory cytokine in a sample from said animal prior to administration of said nutritional composition that comprises said synthetic oligosaccharide preparation.

13. The method of claim 12 , wherein permeability of a gastrointestinal barrier of said animal is decreased relative to permeability of said gastrointestinal barrier of said animal prior to said administering said synthetic oligosaccharide preparation.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2023
From: DSM NUTRITIONAL PRODUCTS, LLC
To: DSM IP ASSETS B.V.
Reel/Frame 063366/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2023
From: MIDORI USA INC.
To: DSM IP ASSETS B.V.
Reel/Frame 063321/0856 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE SECOND ASSIGNOR NAME PREVIOUSLY RECORDED AT REEL: 061404 FRAME: 0320. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 18, 2022
From: KALEIDO BIOSCIENCES, INC.; CADENA BIO, INC.
To: HERCULES CAPITAL, INC.
Reel/Frame 061700/0414 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2022
From: HERCULES CAPITAL, INC.
To: DSM NUTRITIONAL PRODUCTS, LLC
Reel/Frame 061362/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2022
From: KALEIDO BIOSCIENCES, INC.; CARDENA BIO, INC.
To: HERCULES CAPITAL, INC.
Reel/Frame 061404/0320 →
Continuity (3)
Provisional Application 62757500 · Nov 8, 2018
Provisional Application 62757465 · Nov 8, 2018
Related Publication 20220000891A1 · Jan 6, 2022
References Cited (16)
US 20080260696A1 · Massimino · 2008 [cited by applicant]
US 20120196811A1 · Dikovskiy · 2012 [cited by applicant]
US 20160213702A1 · Von Maltzahn · 2016 [cited by applicant]
US 20160366909A1 · Geremia · 2016 [cited by applicant]
CN 102091089 · 2011 [cited by applicant]
CN 107897512 · 2013 [cited by applicant]
DE 10104055 · 2002 [cited by applicant]
JP 2010519921 · 2010 [cited by applicant]
JP 2018509176 · 2018 [cited by applicant]
WO 2017125929A1 · 2017 [cited by applicant]
WO WO2018091759 · 2018 [cited by applicant]
WO WO2018157900A1 · 2018 [cited by examiner]
“Prevention” in Glossary of medical education terms: Parts 1-7. Wojtczak, A., Ed. Medical Teacher. vol. 24, Nos. 2-6 and vol. 25, No. 1&2. 2002. (Year: 2002). [cited by examiner]
San In Lee et al., Difructose dianhydride improves intestinal calcium absorption, wound healing, and barrier function, Scientific Reports, (2018) 8:7813. [cited by applicant]
International Search Report issued by the International Searching Authority in International Application No. PCT/US19/60443, dated Jan. 30, 2020 (3 pages). [cited by applicant]
Written Opinion of the International Searching Authority issued by the International Searching Authority in International Application No. PCT/US19/60443, dated Jan. 30, 2020 (6 pages). [cited by applicant]